SCHEMBL1553680

SCHEMBL1553680

CCCCc1nc(-c2ccc(C(F)(F)F)cc2)sc1COc1ccc(C(=O)NN)c(Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 13/20 0.47
PPARA Q07869 8/20 0.47
PPARG P37231 5/20 0.47
FFAR1 O14842 7/20 0.46
NPC1 O15118 1/20 0.43
ALDH1A1 P00352 1/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43
GSTP1 P09211 1/20 0.43
PTPN1 P18031 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1553871 0.91 PPARD (0.48) PPARDPPARAPPARGFFAR1MAPT
SCHEMBL27651021 0.91 PPARD (0.51) PPARDPPARAPPARGFFAR1GSTP1
SCHEMBL3537625 0.84 PPARD (0.49) PPARDPPARAPPARGFFAR1
SCHEMBL13368436 0.84 PPARD (0.49) PPARDPPARAPPARGFFAR1
SCHEMBL3535769 0.84 PPARD (0.51) PPARDPPARAPPARGFFAR1MAPT
SCHEMBL1554488 0.84 PPARD (0.58) PPARDPPARAPPARGFFAR1NPC1
SCHEMBL14424857 0.83 PPARD (0.50) PPARDPPARAPPARGFFAR1MAPT
SCHEMBL3540343 0.83 PPARD (0.49) PPARDPPARAPPARGFFAR1PTPN1
SCHEMBL3538234 0.83 PPARD (0.49) PPARDPPARAPPARGFFAR1
SCHEMBL3851691 0.81 PPARD (0.48) PPARDPPARAPPARGFFAR1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1735303-B1 1,3,4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS AND THEIR USE THEREOF AVENTIS PHARMA INC (US) 2011-04-27 EP disclosed
US-7576109-B2 1,3,4-oxadiazol-2-ones as PPAR delta modulators and their use thereof AVENTIS PHARMACEUTICALS INC. (US) 2009-08-18 US disclosed
US-7576109-B2 1,3,4-oxadiazol-2-ones as PPAR delta modulators and their use thereof AVENTIS PHARMACEUTICALS INC. (US) 2009-08-18 US disclosed
US-7576109-B2 1,3,4-oxadiazol-2-ones as PPAR delta modulators and their use thereof AVENTIS PHARMACEUTICALS INC. (US) 2009-08-18 US disclosed
US-20070060626-A1 1,3,4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS AND THEIR USE THEREOF AVENTIS PHARMACEUTICALS INC. (US) 2007-03-15 US disclosed
US-20070060626-A1 1,3,4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS AND THEIR USE THEREOF AVENTIS PHARMACEUTICALS INC. (US) 2007-03-15 US disclosed
US-20070060626-A1 1,3,4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS AND THEIR USE THEREOF AVENTIS PHARMACEUTICALS INC. (US) 2007-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060626-A1 1,3,4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS AND THEIR USE THEREOF PPARD, PPARA, PPARG PPARD 1/4885PPARA 2/4885PPARG 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.